Clinical Trial Update: Combination of BTK Inhibitor Overcomes Drug-resistance in Refractory/Relapsed FLT3 Mutant AML [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial update reports a BTK inhibitor combination aimed at overcoming drug resistance in refractory/relapsed FLT3-mutant acute myeloid leukemia (AML) …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• BTK inhibitor

Snippet

Sponsor: Nanfang Hospital, Southern Medical University | Conditions: FLT3-ITD Mutation, Acute Myeloid Leukemia | Phase 2, Phase 3 | Status: UNKNOWN